| Interpretive Data: |
Characteristics: Spontaneous fetal intracranial bleeding in 20% of severe perinatal alloimmune thrombocytopenia (PAT) affected pregnancies; risk of fetal death. Post-transfusion purpura in transfusion recipients with antibodies to a specific platelet antigen.
Incidence: PAT occurs in 1 in 5000 births.
Inheritance: Codominant expression of a and b alleles.
Cause: Women homozygous for a rare b HPA allele with antibodies to the common a allele have a 50% risk for an affected pregnancy if her partner is heterozygous for a allele and 100% if her partner is homozygous for a allele.
Mutations tested: HPA 1, 2, 3, 4, 5, 6, 15 a (common) and b (variant) alleles.
Clinical Sensitivity: 98%
Methodology: Polymerase chain reaction (PCR) followed by melting analysis using fluorescent resonance energy transfer (FRET) probes.
Analytical Sensitivity and Specificity: 99%
Limitations: Mutations other than in HPA 1, 2, 3, 4, 5, 6, 15 will not be detected; furthermore, mutations within the primer or probe regions could affect this assay.
This test is performed pursuant to an agreement with Roche Molecular Systems, Inc.
Please refer to Statement C in the Compliance Statements section in the front of the Laboratory Test Directory.
|
![[ image for: Patient History for Fetal Molecular Testing]](icon_29.jpg){kind=icon}